To increase comparability between treatment groups, propensity score matching was performed using demographic features, body mass index (BMI), glycated hemoglobin (HbA1c), medical history, co-existing treatments, healthcare utilization, and results of laboratory investigations
FIGURE 4 4 Comparative overview of mainstream GLP-1RAs Over the past 2 decades, several GLP-1RAs have entered clinical practice, including short-acting exenatide, intermediate-acting liraglutide, and long-acting formulations such as dulaglutide and semaglutide, as well as the newer dual agonist tirzepatide
There are ongoing phase 2 and 3 trials using setmelanotide to further investigate the role of these medications in obesity [99, 100]
Healthletic BPC-157: a Safe and Convenient Way to Experience Peptide Support Many supplements tout science but fall short on quality or usability
Oral melanotic lesions usually account for 1520% of all the intra-oral lesions and more often than not, such pigmented lesions are first confronted by the primary care physicians